BioVie Inc. (BIVI)

NCM – Real Time Price. Currency in USD

1.32

-0.03 (-2.22%)

At close: May 12, 2026, 4:00 PM EDT

1.33

+0.01 (0.75%)

Pre-market: May 13, 2026, 7:12 AM EDT

09.05.2026

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

09.05.2026

BioVie CEO shares insights into long COVID trial - ICYMI

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined progress in its clinical program targeting long COVID, highlighting both the scale of the unmet need and the potential for a first-in-class treatment. In an interview with Proactive, CEO Cuong Do said that approximately 17 million Americans are affected by long COVID, with symptoms ranging from brain fog and fatigue to more severe functional impairments.

27.04.2026

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim's mechanism of action could potentially address the pathology and progression of neurodegenerative diseases, including Parkinson's disease. To register, click here.

14.04.2026

BioVie abstract on Parkinson's drug accepted for neurology conference

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday an abstract from its mid-stage study of experimental Parkinson's disease treatment bezisterim has been accepted for presentation at an upcoming neurology conference. The abstract, based on the company's SUNRISE-PD trial evaluating bezisterim in patients with early Parkinson's disease, will be presented at the American Academy of Neurology Annual Meeting later this week.

14.04.2026

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson's Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 2026.

11.04.2026

BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson's disease, with CEO Cuong Do highlighting the company's focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while Parkinson's is commonly associated with dopamine deficiency and loss of muscle control, this represents only part of the disease mechanism.

26.03.2026

BioVie targets Parkinson's at its source with lead drug bezisterim

For decades, treatment of Parkinson's disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease's hallmark motor symptoms. But while therapies such as levodopa can temporarily restore movement, they do little to address the underlying neurodegeneration, and often introduce complications of their own.

Videos

No Data

There is no data to display

Press releases

27.04.2026

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

14.04.2026

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

12.02.2026

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

24.12.2025

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioVie Inc. (NASDAQ: BIVI) breached their fiduciary duties to shareholders.

BioVie Inc. (BIVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioVie Inc. (BIVI)

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

BioVie CEO shares insights into long COVID trial - ICYMI

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie abstract on Parkinson's drug accepted for neurology conference

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI

BioVie targets Parkinson's at its source with lead drug bezisterim

Videos

No Data

Press releases

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

BioVie CEO shares insights into long COVID trial - ICYMI

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie abstract on Parkinson's drug accepted for neurology conference

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI

BioVie targets Parkinson's at its source with lead drug bezisterim

Videos

No Data

Press releases

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Search stocks

BioVie Inc. (BIVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioVie Inc. (BIVI)

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

BioVie CEO shares insights into long COVID trial - ICYMI

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie abstract on Parkinson's drug accepted for neurology conference

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI

BioVie targets Parkinson's at its source with lead drug bezisterim

Videos

No Data

Press releases

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

BioVie CEO shares insights into long COVID trial - ICYMI

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie abstract on Parkinson's drug accepted for neurology conference

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI

BioVie targets Parkinson's at its source with lead drug bezisterim

Videos

No Data

Press releases

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS